Gastric Cancer

, Volume 22, Issue 4, pp 731–741 | Cite as

Genome-wide long non-coding RNAs identified a panel of novel plasma biomarkers for gastric cancer diagnosis

  • Rui Zheng
  • Jiayuan Liang
  • Jiafei Lu
  • Shuwei Li
  • Gang Zhang
  • Xiaowei Wang
  • Mengting Liu
  • Weizhi Wang
  • Haiyan Chu
  • Guoquan Tao
  • Qinghong Zhao
  • Meilin Wang
  • Mulong DuEmail author
  • Fulin QiangEmail author
  • Zhengdong ZhangEmail author
Original Article



Although long non-coding RNAs (lncRNAs) are regarded as useful plasma-based biomarkers for cancer detection, the potential diagnostic value of lncRNAs in gastric cancer (GC) remains unclear.


To screen promising lncRNAs biomarkers for GC, we performed genome-wide lncRNA microarray assay between five GC cases plasma and matched healthy controls plasma. The expression of candidate plasma-related lncRNAs were validated in two-phase validation of 446 subjects. The receiver operating characteristic curve was constructed for evaluating diagnostic accuracy. We also determined the origin and stability of plasma lncRNAs, and investigated biological effects of candidate lncRNAs on cellular phenotypes.


A total of 3878 lncRNAs were expressed differentially in GC plasma, among which the top 10 up-regulated lncRNAs were selected for further validation. A two-stage validation revealed that plasma levels of three lncRNAs (FAM49B-AS, GUSBP11, and CTDHUT) were significantly higher in GC plasma as compared with healthy controls (P < 0.05), and the combined area under curve of these lncRNAs was 0.818 (95% CI 0.772–0.864). Moreover, these lncRNAs were stable and detectable in human plasma, and also enriched in extracellular fluid. The expression levels of all three lncRNAs dropped significantly on day 10 after radical surgery compared with preoperative levels (P < 0.05). Also, lncRNA FAM49B-AS significantly promoted GC cell viability and invasion.


Plasma lncRNA FAM49B-AS, GUSBP11 and CTDHUT have a strong potential to serve as noninvasive biomarkers for GC diagnosis.


Plasma LncRNA Diagnosis Biomarker Gastric cancer 



Long non-coding RNAs


Gastric cancer


Confidence interval


Serum pepsinogen


Carbohydrate antigen 242


Carbohydrate antigen 724


Carcinoembryonic antigen


Non-coding RNAs


Quantitative real-time PCR


Propidium iodide


Cycle threshold


Receiver operating characteristic


Area under the curve


CTD highly upregulated transcript



This study was supported by National Natural Science Foundation of China (81473049, 81773538 and 81773539), Jiangsu Provincial Science and Technology Innovation Team, Jiangsu Provincial Postdoctoral Science Foundation funded project (1501081C), China Postdoctoral Science Foundation funded project (2015M580449), Collaborative Innovation Center For Cancer Personalized Medicine, and the Priority Academic Program Development of Jiangsu Higher Education Institutions (Public Health and Preventive Medicine).

Author contributions

ZZ, QF, DM and WM designed the research. WW, ZQ, TG and ZG recruited samples. ZR, LJ, LJ, LS, WX, LM and CH contributed reagents/materials/analysis tools. ZR, LJ and LJ wrote the manuscript. All authors reviewed the manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Human rights statement and informed consent

The research was approved by the Ethics Committee of Nanjing Medical University. Informed consent was obtained from all subjects before they were included in this study.

Supplementary material

10120_2018_915_MOESM1_ESM.docx (6.9 mb)
Supplementary material 1 (DOCX 7050 KB)


  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30.CrossRefGoogle Scholar
  2. 2.
    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRefGoogle Scholar
  3. 3.
    Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32.CrossRefGoogle Scholar
  4. 4.
    Kunz PL, Gubens M, Fisher GA, Ford JM, Lichtensztajn DY, Clarke CA. Long-term survivors of gastric cancer: a California population-based study. J Clin Oncol. 2012;30:3507–15.CrossRefGoogle Scholar
  5. 5.
    Camargo MC, Kim WH, Chiaravalli AM, Kim KM, Corvalan AH, Matsuo K, et al. Improved survival of gastric cancer with tumour Epstein–Barr virus positivity: an international pooled analysis. Gut. 2014;63:236–43.CrossRefGoogle Scholar
  6. 6.
    Zhou YC, Zhao HJ, Shen LZ. Preoperative serum CEA and CA19-9 in gastric cancer—a single tertiary hospital study of 1,075 cases. Asian Pac J Cancer Prev. 2015;16:2685–91.CrossRefGoogle Scholar
  7. 7.
    Tian SB, Yu JC, Kang WM, Ma ZQ, Ye X, Cao ZJ, et al. Combined detection of CEA, CA 19-9, CA 242 and CA 50 in the diagnosis and prognosis of resectable gastric cancer. Asian Pac J Cancer Prev. 2014;15:6295–300.CrossRefGoogle Scholar
  8. 8.
    Mattar R, Alves de Andrade CR, DiFavero GM, Gama-Rodrigues JJ, Laudanna AA. Preoperative serum levels of CA 72-4, CEA, CA 19-9, and alpha-fetoprotein in patients with gastric cancer. Rev Hosp Clin Fac Med Sao Paulo. 2002;57:89–92.CrossRefGoogle Scholar
  9. 9.
    Zhang K, Shi H, Xi H, Wu X, Cui J, Gao Y, et al. Genome-wide lncRNA microarray profiling identifies novel circulating lncRNAs for detection of gastric cancer. Theranostics. 2017;7:213–27.CrossRefGoogle Scholar
  10. 10.
    Mishra PJ. Non-coding RNAs as clinical biomarkers for cancer diagnosis and prognosis. Expert Rev Mol Diagn. 2014;14(8):917–9CrossRefGoogle Scholar
  11. 11.
    Li PF, Chen SC, Xia T, Jiang XM, Shao YF, Xiao BX, et al. Non-coding RNAs and gastric cancer. World J Gastroenterol. 2014;20:5411–9.CrossRefGoogle Scholar
  12. 12.
    Shi T, Gao G, Cao Y. Long noncoding RNAs as novel biomarkers have a promising future in cancer diagnostics. Dis Markers. 2016;9085195:10.Google Scholar
  13. 13.
    Zhang H, Chen Z, Wang X, Huang Z, He Z, Chen Y. Long non-coding RNA: a new player in cancer. J Hematol Oncol. 2013;6:1756–8722.CrossRefGoogle Scholar
  14. 14.
    Qiu MT, Hu JW, Yin R, Xu L. Long noncoding RNA: an emerging paradigm of cancer research. Tumour Biol. 2013;34:613–20.CrossRefGoogle Scholar
  15. 15.
    Ren S, Wang F, Shen J, Sun Y, Xu W, Lu J, et al. Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer. Eur J Cancer. 2013;49:2949–59.CrossRefGoogle Scholar
  16. 16.
    Amorim M, Salta S, Henrique R, Jeronimo C. Decoding the usefulness of non-coding RNAs as breast cancer markers. J Transl Med. 2016;14:016–1025.CrossRefGoogle Scholar
  17. 17.
    Tong YS, Wang XW, Zhou XL, Liu ZH, Yang TX, Shi WH, et al. Identification of the long non-coding RNA POU3F3 in plasma as a novel biomarker for diagnosis of esophageal squamous cell carcinoma. Mol Cancer. 2015;14:1476–4598.CrossRefGoogle Scholar
  18. 18.
    Li Q, Shao Y, Zhang X, Zheng T, Miao M, Qin L, et al. Plasma long noncoding RNA protected by exosomes as a potential stable biomarker for gastric cancer. Tumour Biol. 2015;36:2007–12.CrossRefGoogle Scholar
  19. 19.
    Pang Q, Ge J, Shao Y, Sun W, Song H, Xia T, et al. Increased expression of long intergenic non-coding RNA LINC00152 in gastric cancer and its clinical significance. Tumour Biol. 2014;35:5441–7.CrossRefGoogle Scholar
  20. 20.
    Song H, Sun W, Ye G, Ding X, Liu Z, Zhang S, et al. Long non-coding RNA expression profile in human gastric cancer and its clinical significances. J Transl Med. 2013;11:1479–5876.CrossRefGoogle Scholar
  21. 21.
    Zhou X, Yin C, Dang Y, Ye F, Zhang G. Identification of the long non-coding RNA H19 in plasma as a novel biomarker for diagnosis of gastric cancer. Sci Rep. 2015;5:11516.CrossRefGoogle Scholar
  22. 22.
    Liu J, Wang J, Song Y, Ma B, Luo J, Ni Z, et al. A panel consisting of three novel circulating lncRNAs, is it a predictive tool for gastric cancer? J Cell Mol Med. 2018;26:13640.Google Scholar
  23. 23.
    Gong C, Li Z, Ramanujan K, Clay I, Zhang Y, Lemire-Brachat S, et al. A long non-coding RNA, LncMyoD, regulates skeletal muscle differentiation by blocking IMP2-mediated mRNA translation. Dev Cell. 2015;34:181–91.CrossRefGoogle Scholar
  24. 24.
    Duraes C, Almeida GM, Seruca R, Oliveira C, Carneiro F. Biomarkers for gastric cancer: prognostic, predictive or targets of therapy? Virchows Arch. 2014;464:367–78.CrossRefGoogle Scholar
  25. 25.
    Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet. 2016;388:2654–64.CrossRefGoogle Scholar
  26. 26.
    Arita T, Ichikawa D, Konishi H, Komatsu S, Shiozaki A, Shoda K, et al. Circulating long non-coding RNAs in plasma of patients with gastric cancer. Anticancer Res. 2013;33:3185–93.Google Scholar
  27. 27.
    Liu Z, Shao Y, Tan L, Shi H, Chen S, Guo J. Clinical significance of the low expression of FER1L4 in gastric cancer patients. Tumour Biol. 2014;35:9613–7.CrossRefGoogle Scholar
  28. 28.
    Shao Y, Ye M, Jiang X, Sun W, Ding X, Liu Z, et al. Gastric juice long noncoding RNA used as a tumor marker for screening gastric cancer. Cancer. 2014;120:3320–8.CrossRefGoogle Scholar
  29. 29.
    Toiyama Y, Takahashi M, Hur K, Nagasaka T, Tanaka K, Inoue Y, et al. Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst. 2013;105:849–59.CrossRefGoogle Scholar
  30. 30.
    Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res. 2017;77:3965–81.CrossRefGoogle Scholar
  31. 31.
    Hotta T, Takifuji K, Yokoyama S, Matsuda K, Oku Y, Nasu T, et al. Impact of the post/preoperative serum CEA ratio on the survival of patients with rectal cancer. Surg Today. 2014;44:2106–15.CrossRefGoogle Scholar
  32. 32.
    Lorenzen JM, Schauerte C, Kielstein JT, Hubner A, Martino F, Fiedler J, et al. Circulating long noncoding RNATapSaki is a predictor of mortality in critically ill patients with acute kidney injury. Clin Chem. 2015;61:191–201.CrossRefGoogle Scholar
  33. 33.
    Dong L, Qi P, Xu MD, Ni SJ, Huang D, Xu QH, et al. Circulating CUDR, LSINCT-5 and PTENP1 long noncoding RNAs in sera distinguish patients with gastric cancer from healthy controls. Int J Cancer. 2015;137:1128–35.CrossRefGoogle Scholar
  34. 34.
    Isin M, Ozgur E, Cetin G, Erten N, Aktan M, Gezer U, et al. Investigation of circulating lncRNAs in B-cell neoplasms. Clin Chim Acta. 2014;431:255–9.CrossRefGoogle Scholar
  35. 35.
    Chattaragada MS, Riganti C, Sassoe M, Principe M, Santamorena MM, Roux C, et al. FAM49B, a novel regulator of mitochondrial function and integrity that suppresses tumor metastasis. Oncogene. 2018;37:697–709.CrossRefGoogle Scholar
  36. 36.
    Cao W, Liu JN, Liu Z, Wang X, Han ZG, Ji T, et al. A three-lncRNA signature derived from the Atlas of ncRNA in cancer (TANRIC) database predicts the survival of patients with head and neck squamous cell carcinoma. Oral Oncol. 2017;65:94–101.CrossRefGoogle Scholar
  37. 37.
    Wang F, Meng W, Wang B, Qiao L. Helicobacter pylori-induced gastric inflammation and gastric cancer. Cancer Lett. 2014;345:196–202.CrossRefGoogle Scholar

Copyright information

© The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2019

Authors and Affiliations

  • Rui Zheng
    • 1
    • 2
  • Jiayuan Liang
    • 1
    • 2
  • Jiafei Lu
    • 1
    • 2
  • Shuwei Li
    • 1
    • 2
  • Gang Zhang
    • 1
    • 2
    • 3
  • Xiaowei Wang
    • 1
    • 2
  • Mengting Liu
    • 1
    • 2
  • Weizhi Wang
    • 4
  • Haiyan Chu
    • 1
    • 2
  • Guoquan Tao
    • 5
  • Qinghong Zhao
    • 6
  • Meilin Wang
    • 1
    • 2
    • 7
  • Mulong Du
    • 1
    • 8
    Email author
  • Fulin Qiang
    • 9
    Email author
  • Zhengdong Zhang
    • 1
    • 2
    • 7
    Email author
  1. 1.Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized MedicineNanjing Medical UniversityNanjingChina
  2. 2.Department of Genetic Toxicology, The Key Laboratory of Modern Toxicology of Ministry of Education, School of Public HealthNanjing Medical UniversityNanjingChina
  3. 3.Department of NeurologyThe Affiliated Children’s Hospital of Nanjing Medical UniversityNanjingChina
  4. 4.Department of General SurgeryThe First Affiliated Hospital of Nanjing Medical UniversityNanjingChina
  5. 5.Department of General SurgeryThe Affiliated Huaian No.1 People’s Hospital of Nanjing Medical UniversityHuai’anChina
  6. 6.Department of General SurgeryThe Second Affiliated Hospital of Nanjing Medical UniversityNanjingChina
  7. 7.Department of Environmental Genomics, Center for Global Health, School of Public HealthNanjing Medical UniversityNanjingChina
  8. 8.Department of Biostatistics, Center for Global Health, School of Public HealthNanjing Medical UniversityNanjingChina
  9. 9.Department of Core LaboratoryNantong Tumor HospitalNantongChina

Personalised recommendations